Should you buy Personalis stock now?
Yes, the technical signal for Personalis is currently BUY. Personalis trades at $13.35 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.154 with falling momentum (signal: 0.247); RSI is at 56.6 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $13.88 points to 4.0% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Personalis stock?
The average analyst price target for Personalis is $13.88. The current price is $13.35, which gives an upside of 4.0%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $12.49 and $15.27.
Is Personalis a dividend stock?
No, Personalis does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Personalis stock?
Personalis is rated as a stock with extreme risk. the annual standard deviation is 91.0%, which classifies the stock as extreme risk.
Is Personalis overvalued?
Personalis is considered fairly valued – the price is close to the analyst price target. Personalis has the following valuation ratios: a P/S ratio of 22.4, a P/B ratio of 5.3. The stock trades close to the analyst price target and is considered fairly valued.
Is Personalis overbought?
No, Personalis is not overbought. RSI is at 56.6 (neutral zone). The technical indicators show: RSI is at 56.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.9% below the 20-day average (short-term downtrend). In addition, MACD is positive, but momentum is falling.
When is the next Personalis earnings report?
The date of the next earnings report for Personalis has not been published yet. Check the company's investor calendar for updates.
Is Personalis shorted?
Yes, Personalis is shorted with 16.7% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Personalis stock?
No, insiders are not buying Personalis shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 9 sales. On a net basis, 6,819,446 $ worth of shares were sold. Across the last 20 reported transactions, the split is 7 purchases and 13 sales, with a net 7,633,814 $ sold. Active sellers include Chen Richard, Hall Christopher M, Tachibana Aaron and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Personalis a good stock?
Based on our total score, Personalis is rated as a poor stock with a total score of 34 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 10/100, Quality: 1/100, Momentum: 91/100. In addition: technical signal: Strong Buy. Whether Personalis is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Personalis stock?
The outlook for Personalis based on current data: the average analyst price target is $13.88 (+4.0%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Personalis stock moving?
Personalis is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 16.7% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Personalis go?
The average analyst price target for Personalis is $13.88, which corresponds to a potential gain of 4.0% from the current price of $13.35. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Personalis fall?
We lack enough history to give a specific floor for Personalis. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Personalis do?
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurr... The company belongs to the Sundhed sector, more specifically the Diagnostics & Research industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Personalis as an investment.
Did Personalis raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Personalis. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Personalis making money or losing money?
No, Personalis is currently not making money — the company is losing money with a negative profit margin of -148.1%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Personalis go bankrupt?
The bankruptcy risk of Personalis is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.39 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 33% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Personalis have a lot of debt?
No, Personalis has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 33%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
